ADVERTISEMENT

Survivor Story: Living with Multiple Myeloma

A survivor's story of living with multiple myeloma.

BY CINDY CHMIELEWSKI
PUBLISHED THURSDAY, JANUARY 26, 2012
Two years prior to my cancer diagnosis, an orthopedist diagnosed me with degenerative disc disease when I went to him to help figure out what was causing excruciating lower back pain.

I was treated with pain medication and physical therapy, but my pain grew worse. After two years of treatment, an X-ray revealed several compression fractures, which ultimately led to my diagnosis of stage 3A multiple myeloma.

I have been on several chemotherapy protocols and have had a stem cell transplantation.

Although I never achieved more than a partial response to my treatments, I am confident that with continued therapy, I will someday be able to say I am cancer-free. It is also reassuring to know that there are many drugs in the pipeline for when my myeloma becomes resistant to my current therapy.

To strengthen my bones, I receive a monthly intravenous bisphosphonate; I take calcium and vitamin D supplements daily; I spend at least 15 minutes a day in the sun; I include dark leafy vegetables in my diet; and I exercise. Since my bones are fragile, I need to be careful when exercising, so I participate in an aquatics program and walk daily with my dog. My goal is to walk a half-marathon next year. I am gradually adding gentle yoga and core-strengthening exercises to my routine.

I am living a full, active life while I am in treatment. I have learned to take things one day at a time, appreciate every day and be my own health advocate.

From "A Patient's Guide to Multiple Myeloma," published in the Winter 2011 issue of CURE. Download the full guide here.

ADVERTISEMENT
Related Articles
FDA Approves Farydak for Multiple Myeloma
BY SILAS INMAN
The FDA has approved Farydak (panobinostat) in combination with Velcade (bortezomib) and dexamethasone for patients with multiple myeloma who receive prior treatment with Velcade and an immunomodulatory (IMiD) agent, based on results of the PANORAMA-1 trial.
Revlimid Approved for Newly Diagnosed Multiple Myeloma
BY JASON M. BRODERICK
The FDA has approved Revlimid plus dexamethasone in newly diagnosed patients with multiple myeloma based on findings from the phase 3 FIRST trial.
Ixazomib Delays Myeloma Progression  in Phase 3 Trial
BY ANDREW J. ROTH
Ixazomib, also known as MLN9708, met its primary endpoint of improving progression-free survival at an interim analysis of a phase 3 trial of relapsed or refractory multiple myeloma.
Several Cancer Therapies Up for FDA Review in 2015
BY ANITA T. SHAFFER
The Food and Drug Administration’s calendar for making decisions on new cancer drugs and indications is taking shape for 2015, and the clock is ticking on at least 13 applications for novel agents and new therapeutic settings for existing drugs.
Experimental Drug Elotuzumab Produces Impressive Response Rate in Relapsed/Refractory Multiple Myeloma
BY WAYNE KUZNAR
Treatment with the experimental agent elotuzumab in combination with Revlimid and dexamethasone demonstrated encouraging efficacy in patients with relapsed/refractory multiple myeloma in a phase 1b/2 study.
Related Videos
Anne Quinn Young, of the MMRF, Discusses Immunotherapies Being Studied in Multiple Myeloma
Anne Quinn Young, of the Multiple Myeloma Research Foundation, discusses some of the antibodies that are being studied in multiple myeloma.
Myeloma Expert Brian Durie Discusses the ASPIRE Trial
Brian G.M. Durie, an expert in multiple myeloma at Cedars-Sinai in Los Angeles, Calif., and chairman of the International Myeloma Foundation, discusses the ASPIRE trial for patients with relapsed myeloma.
MMRF’s CoMMpass Study Highlights and Moves Research of Myeloma Forward
Anne Young Quinn, of the MMRF, explains the catalyst behind the CoMMpass study and how it may be changing the future of myeloma treatment.
Recent Publications
  • photo
    photo
    photo
    photo
    photo
  • photo
    photo
    photo
    photo
    photo
ADVERTISEMENT
$auto_registration$